Q fever seroprevalence in parturient women: the EQRUN cross-sectional study on Reunion Island

BMC Infectious Diseases

Table 3 Adverse pregnancy outcomes associated with Q fever seropositivity in bivariate analysis, among 1112 parturient women, Reunion island, January to July 2014

Adverse	*Exposure variable:Coxiella burnetiiPhase 2 IgG ≥ 1:64*
pregnancy outcomes	n	Crude %	Crude PPR	95% CI	*P value*
Composite outcome^a					0.567
In seropositive	52 / 203	25.6	0.93	0.71–1.20
In seronegative	251 / 909	27.5	1
Preterm birth					0.775
In seropositive	11 / 203	5.4	0.91	0.48–1.71
In seronegative	54 / 909	5.9	1
Small-for-gestational age					0.823
In seropositive	41 / 203	20.2	0.97	0.71–1.31
In seronegative	190 / 909	20.9	1
Exposure variable: **Coxiella burnetiiPhase 2 IgG ≥ 1:256 or Phase 2 IgM ≥ 1:48**
Composite outcome^a					0.801
In seropositive	13 / 45	28.9	1.06	0.66–1.70
In seronegative	290 / 1067	27.2	1
Preterm birth					0.319
In seropositive	1 / 45	2.2	0.37	0.05–2.61
In seronegative	64 / 1067	6.0	1
Small-for-gestational age					0.897
In seropositive	9 / 45	20.0	0.96	0.53–1.74
In seronegative	222 / 1067	20.8	1

Data are numbers, crude seropositive rates (%), crude prevalence proportion ratios (PPR) and 95% confidence intervals (95% CI). NA: not assessed. P values are given for Wald tests and not for crude Pearson chi2 tests
^aRecurrent miscarriage, stillbirth, or preterm birth, small-for-gestational age, congenital malformations, oligohydramnios or polyhydramnios

ISSN: 1471-2334